Frequency of renal impairment, advanced age, obesity and cancer in venous thromboembolism patients in clinical practice
暂无分享,去创建一个
S. Kahn | M. Kovacs | J. Goodwin | L. Cook | L. Cook
[1] T. Lecompte,et al. Low-molecular weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. , 2008 .
[2] F. Dentali,et al. Meta-Analysis: Low-Molecular-Weight Heparin and Bleeding in Patients with Severe Renal Insufficiency , 2006, Annals of Internal Medicine.
[3] J. Douketis,et al. Low-molecular-weight heparins for the treatment of acute coronary syndrome and venous thromboembolism in patients with chronic renal insufficiency. , 2006, Thrombosis research.
[4] M. Monreal,et al. Venous thromboembolism in very elderly patients: findings from a prospective registry (RIETE). , 2006, Haematologica.
[5] Joseph A. Smith,et al. Clinical practice. Treatment of deep-vein thrombosis. , 2005, The Journal of urology.
[6] A. Shillington,et al. Treatment of venous thromboembolism: adherence to guidelines and impact of physician knowledge, attitudes, and beliefs. , 2005, Journal of vascular surgery.
[7] F. García-Bragado,et al. The influence of extreme body weight on clinical outcome of patients with venous thromboembolism: findings from a prospective registry (RIETE) , 2005, Journal of thrombosis and haemostasis : JTH.
[8] M. Kovacs,et al. The safety of dosing dalteparin based on actual body weight for the treatment of acute venous thromboembolism in obese patients , 2005, Journal of thrombosis and haemostasis : JTH.
[9] L. Lalonde,et al. Dosage of enoxaparin among obese and renal impairment patients. , 2005, Thrombosis research.
[10] J. Hirsh,et al. Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. , 2004, Chest.
[11] Giancarlo Agnelli,et al. Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. , 2004, Chest.
[12] Jeffrey S. Ginsberg,et al. Treatment of Deep-Vein Thrombosis , 2004 .
[13] M. Prins,et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. , 2003, The New England journal of medicine.
[14] J. Hirsh,et al. Is impaired renal function a contraindication to the use of low-molecular-weight heparin? , 2002, Archives of internal medicine.
[15] R. Poveda,et al. Goodpasture syndrome during the course of a Schönlein-Henoch purpura. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[16] J. Barrett,et al. Dosing in Heavy-weight/Obese Patients with the LMWH, Tinzaparin: A Pharmacodynamic Study , 2002, Thrombosis and Haemostasis.
[17] Ethan M Balk,et al. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[18] Kdoqi Disclaimer. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[19] R. Hull,et al. Antithrombotic therapy for venous thromboembolic disease. , 1986, Chest.